Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer.
Germline mutations in CHEK2 have been associated with a range of cancer types but little is known about disease risks conveyed by CHEK2 mutations outside of the context of breast and prostate cancer. To investigate whether CHEK2 mutations confer an increased risk of bladder cancer, we genotyped 416 unselected cases of bladder cancer and 3,313 controls from Poland for 4 founder alleles in the CHEK2 gene, each of which has been associated with an increased risk of cancer at other sites. A CHEK2 mutation (all variants combined) was found in 10.6% of the cancer cases and in 5.9% of the controls (OR = 1.9; 95%CI 1.3-2.7; p = 0.0003). We conclude that CHEK2 mutations increase the risk of bladder cancer in the population.
Złowocka
Elzbieta
E
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. elzunik@wp.pl
Cybulski
Cezary
C
Górski
Bohdan
B
Debniak
Tadeusz
T
Słojewski
Marcin
M
Wokołorczyk
Dominika
D
Serrano-Fernández
Pablo
P
Matyjasik
Joanna
J
van de Wetering
Thierry
T
Sikorski
Andrzej
A
Scott
Rodney J
RJ
Lubiński
Jan
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D064447:Checkpoint Kinase 2; D004252:DNA Mutational Analysis; D005260:Female; D018095:Germ-Line Mutation; D006801:Humans; D008297:Male; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D012307:Risk Factors; D012907:Smoking; D001749:Urinary Bladder Neoplasms / Q000201:enzymology / Q000235:genetics*
D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases